Results 141 to 150 of about 697,452 (285)

Observing nociceptive detection thresholds and evoked potentials in diabetic patients with and without painful neuropathy

Exploration of Neuroscience
Aim: Diabetic polyneuropathy is the most described complication in patients with diabetes mellitus. A significant percentage of these patients experience disabling neuropathic pain (painful diabetic polyneuropathy).
Tom Berfelo, Imre P. Krabbenbos, Boudewijn van den Berg, Silvano R. Gefferie, Jan R. Buitenweg   +4 more
doaj   +1 more source

Comparative analysis of clinical and electroneuromyographic indicators in patients with secondary polyneuropathy

Бюллетень сибирской медицины, 2012
Analysis of clinical and electroneuromyographic performance of two groups of patients with secondary polyneuropathy showed that diabetic neuropathy affects the peripheral nerves of the lower extremities, whereas in polyneuropathy of mixed etiology ...
Ye. S. Korolyova, R. B. Tsyrenzhapova, V. M. Alifirova, N. S. Novikova   +3 more
doaj   +1 more source

Role of α-Lipoic Acid in Diabetic Polyneuropathy Treatment

Biomolecules & Biomedicine, 2008
Diabetic neuropathy represents late diabetes complications, and diabetes duration and long-term hyperglycemia are the main reasons for polyneuropathy. The goal was to estimate the effects of alpha-lipoic acid on symptoms of diabetic neuropathy after 600
Azra Bureković, Mirsada Terzić, Salem Alajbegović, Zoran Vukojević, Nedžad Hadžić   +4 more
doaj   +1 more source

Comparative effectiveness of combination therapy with SGLT‐2 inhibitors and GLP‐1 RAs compared with SGLT‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3273-3284, April 2026.
Abstract Aims To evaluate the effectiveness of combination therapy with sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) compared with continued SGLT‐2 inhibitor therapy in routine practice among individuals with type 2 diabetes.
Gregor A. Maier, Beata Hennig, Wolfgang Rathmann, Oliver Kuss   +3 more
wiley   +1 more source

Current status and future directions of botulinum neurotoxins for targeting pain processing. [PDF]

, 2015
Current evidence suggests that botulinum neurotoxins (BoNTs) A1 and B1, given locally into peripheral tissues such as skin, muscles, and joints, alter nociceptive processing otherwise initiated by inflammation or nerve injury in animal models and humans.
Pellett, Sabine, Ramachandran, Roshni, Yaksh, Tony L   +2 more
core   +2 more sources

[Diabetic peripheral polyneuropathy].

Problemy endokrinologii, 1977
Pain, tactile, vibration and temperature sensitivity, and also electroexcitability of individual nerves were determined. Neuropathy incidence was almost the same among males and females. There was found no association between neuropathy and excessive weight of the patients and the type of treatment. The frequency of affection increased with the advance
Sh G, Iuldashev, A M, Kaĭlakov
openaire   +1 more source

Isometric knee extension force in Japanese type 2 diabetic patients without apparent diabetic polyneuropathy: Data from the Multicenter Survey of the Isometric Lower Extremity Strength in Type 2 Diabetes study

SAGE Open Medicine, 2019
Objectives: To determine standard reference values for isometric knee extension force using a cohort of Japanese type 2 diabetic patients without diabetic polyneuropathy.
T. Nomura, T. Ishiguro, Masayoshi Ohira, H. Oka, Y. Ikeda   +4 more
semanticscholar   +1 more source

Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO‐TTRansform Trial

European Journal of Neurology, Volume 33, Issue 4, April 2026.
In this exploratory analysis of the NEURO‐TTRansform Phase 3 trial, the efficacy of eplontersen was evaluated in patients with early‐ or late‐onset Val30Met (p.Val50Met) or non‐Val30Met hereditary transthyretin amyloidosis with polyneuropathy. Eplontersen halted neuropathy impairment as measured by the mNIS+7 composite score and improved Norfolk QoL‐DN
Julian D. Gillmore, David Adams, Markus Weiler, Ahmad Masri, Laura Obici, Jonatan Nåtman, T. Jesse Kwoh, Barry Reicher, James Revkin, Márcia Waddington Cruz, Morie Gertz, Chi‐Chao Chao   +11 more
wiley   +1 more source

Altered Semmes–Weinstein monofilament test results are associated with oxidative stress markers in type 2 diabetic subjects

Journal of Translational Medicine, 2017
Background Different lines of evidence suggest that oxidative stress (OS) is implicated in the pathogenesis of diabetic neuropathy. The Semmes–Weinstein monofilament (SWM) test is an efficient tool for evaluating diabetic polyneuropathy and diabetic foot.
Sergio Martinez-Hervás, Mercedes Molina Mendez, José Folgado, Carmen Tormos, Pilar Ascaso, Marta Peiró, Jose T. Real, Juan F. Ascaso   +7 more
doaj   +1 more source

Adaptação transcultural para o português brasileiro do Michigan Neuropathy Screening Instrument : MNSI-Brasil [PDF]

, 2016
Desde 1994, o Centro de Treinamento e Pesquisa em Diabetes da Universidade de Michigan propôs um instrumento não ainda adaptado para uso no Brasil para mensurar neuropatias.
Azevedo, Diego Igor de Oliveira, Bezerra, Arthur Rodrigues, Botelho, Kárenn Klycia Pereira, Martins, Emerson Fachin, Oliveira, Franassis Barbosa de, Santos-Couto-Paz, Clarissa Cardoso dos   +5 more
core   +1 more source